Every company we cover is scored on 100 weighted points by three independent analysts before a single word is published. Two frameworks, one standard.
Exactis 100™ breaks each company down into six weighted categories. Every category is scored independently by three analysts, then averaged into a single consensus number out of 100 — removing any one analyst's bias from the final call.
A score of 90+ signals maximum conviction. Below 75, a company doesn't get published at all — regardless of how much research went into it.
Biotechnology and growth companies create value in different ways, so we score them differently — but every company still passes through the same three-analyst consensus process.
Built for biotechnology and life sciences — weighted toward clinical catalysts and scientific differentiation.
Built for AI, technology, and defense & security — weighted toward market potential and valuation discipline.
Three analysts score independently. The published number is the average — no single opinion decides.
Become a member for full access to every scored analysis as it publishes.
Become a Member →